A bivalent vaccine It consists of one doseupdated”Or booster that includes a component of the original virus strain of COVID-19 and a component of Omicron variant to provide better protection. In UnoTV.com We explain everything you need to know about these doses.
Recently, the Food and Drug Administration (FDA) from the United States authorized booster shots COVID-19 adapted to Omicron from Modern y Pfizer for children, a measure that will expand the vaccination campaign carried out in this country, something that has not yet taken place in Mexico.
What are the bivalent vaccines against COVID-19 applied in the United States?
According to hospital information Children nationwidea bivalent vaccine contains components of mRNA of two viral strains. The new booster dose against COVID-19 contains mRNA from the original strain of SARS-CoV-2.
On the contrary, the first vaccines applied against the COVID-19 were monovalent, that is, they contained an mRNA component from a single viral strain; in the case of the initial doses developed by the pandemicwere made from the original stock of SARS-CoV-2.
“The bivalent push of COVID-19 occurred because the BA.4 / BA.5 strains of the omcron variant currently cause the majority of COVID-19 cases in the United States.”
Children nationwide
According to FDAs bivalent vaccines contra COVID-19 they can help protect against serious illness, hospitalization and death. To the extent that virus changes and your immunity naturally decreases over time, you may lose some of that protection.
What are the “up-to-date” vaccines managed in the United States?
This Wednesday, October 12, the FDA authorized formulations bivalent vaccines Modern y Pfizer-BioNTech contra COVID-19 to be used as a single booster dose at least two months after completion of the primary or booster vaccination.
The bivalent vaccine from Modern It is authorized for use as a single booster dose in persons aged 6 years and older. For its part, that of Pfizer-BioNTech It is authorized for use as a single booster dose in persons aged 5 years and older.
How is suitability for these doses determined?
The FDA details that eligibility for a booster depends on age, when the primary vaccination was completed, or when you received the most recent booster dose of a monovalent influenza vaccine. COVID-19. Secondly, Children nationwide list eligibility for each bivalent dosis:
- Moderna bivalent vaccine is authorized as a single booster dose in persons aged 18 years and over.
- Pfizer’s bivalent vaccine is authorized as a single booster dose in persons over 12 years of age.
Both are approved as a single dose of reinforcement at least 2 months later vaccination primary or reserve. The latest arrangement in United States of America allows you to apply both doses in children under the age of 5 and 6 years and older.
- Pfizer’s monovalent vaccine remains licensed as a booster dose only in children aged 5 to 11 years.
- The Moderna (6 months and up) and Pfizer (6 months and up) monovalent vaccines remain authorized to complete the primary vaccine series.
A single booster dose with a bivalent vaccine updated provides broad protection against COVID-19 and should provide better protection against the variant Omicron currently in circulation.
